Wonder Cure Pharmaceuticals P Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.33 M
- Company Age 30 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 8.55 Cr
- Revenue Growth 239.49%
- Profit Growth 516.34%
- Ebitda -6.89%
- Net Worth 13.51%
- Total Assets 9.96%
About Wonder Cure Pharmaceuticals P
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1994PTC079343
-
Company No.
079343
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Jun 1994
-
Date of AGM
18 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Wonder Cure Pharmaceuticals P?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Golechha
|
Director | 22-Aug-2006 | Current |
|
Sudha Golechha
|
Director | 22-Aug-2006 | Current |
|
Umang Golechha
|
Director | 17-Aug-2017 | Current |
Financial Performance of Wonder Cure Pharmaceuticals P.
Wonder Cure Pharmaceuticals P Ltd, for the financial year ended 2023, experienced significant growth in revenue, with a 239.49% increase. The company also saw a substantial improvement in profitability, with a 516.34% increase in profit. The company's net worth Soared by an impressive increase of 13.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wonder Cure Pharmaceuticals P?
In 2023, Wonder Cure Pharmaceuticals P had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
_PRIVATE_LIMITED.webp)
Longulf Trading (India) Private LimitedRajesh Golechha and Umang Golechha are mutual person
-
Azure Tree Enviro Farms Private LimitedSudha Golechha is a mutual person
-
Aura Orchards Private Limited
Sudha Golechha is a mutual person
-
Amber Orchards Private Limited
Sudha Golechha is a mutual person
-
Abhiruchi Orchards Private Limited
Sudha Golechha is a mutual person
-
Ambrosia Enviro Farms Private Limited
Sudha Golechha is a mutual person
Charges (Loans)
₹0
₹85.50 M
Charges Breakdown by Lending Institutions
- Others : 8.55 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Nov 2021 | Others | ₹4.00 Cr | Satisfied |
| 10 Dec 2020 | Others | ₹4.55 Cr | Satisfied |
How Many Employees Work at Wonder Cure Pharmaceuticals P?
Unlock and access historical data on people associated with Wonder Cure Pharmaceuticals P, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wonder Cure Pharmaceuticals P, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wonder Cure Pharmaceuticals P's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
